314 results about "Antibiotics therapy" patented technology

A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

The invention relates to a composite probiotic bacterium microecological preparation and a preparation method thereof. The preparation is prepared by mixing 1.0 to 20 percent of composite microbial bacterium powder, 5.0 to 50 percent of composite oligosaccharide, 30 to 80 percent of auxiliary protective carrier and 0.1 to 0.2 percent of edible essence. The composite probiotic bacterium microecological preparation is prepared from a beneficial microbial preparation and a microbial growth-promoting factor, namely the oligosaccharide, through special combination and technological recombination. The composite probiotic bacterium microecological preparation has the advantages that beneficial active bacteria and the oligosaccharide promote each other, so that the composite probiotic bacterium microecological preparation has the advantages of obviously improving the microecological environment of the whole intestine and contributing to the digestion, preventing and treating intestine diseases, treating diarrhea, chronic diarrhea, diarrhea which can not be cured by antibiotic, constipation, dyspepsia and abdominal distension which are caused by intestine dysbacteriosis, recovering the intestine flora balance, protecting the liver, reinforcing the functions of detoxication and toxin expulsion of the liver, reinforcing the disease prevention and resistance such as the resistance of human body, and the like.

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

Class A beta-lactamase may be used for reducing side-effects in the intestine associated with antibiotic therapy with a combination of beta-lactam antibiotic and beta-lactamase inhibitor.

A convertible multi-lumen catheter that may be used for hemodialysis or other indications involving infusion and / or withdrawal of fluids from the body. Unlike existing catheters having a set number of lumens which may limit their utility as both short and long-term venous vascular devices, the catheter of the invention allows one or more additional lumens during the acute phase of catheter use with removal of these lumens (i.e. conversion) for more permanent use. A typical example of this would be a triple lumen device for hemodialysis and antibiotic therapy during an acute infection with conversion to a chronic dual lumen hemodialysis catheter after successful treatment of the infection. The lumen is permanently or semi-permanently blocked using a biocompatible plastic obturator that is inserted into the unused lumen and locked and / or glued into place.

The invention discloses antibacterial and antitumor application of exosomes secreted by NK cells (aNK) activated by transmembrane IL-21 and multiple miRNAs contained in the exosomes, and provides a new method for bacterial infection and antitumor treatment. The method has the advantages that 1, the method is different from antibiotic treatment, and exosome antibiosis has lower side effects; 2, effects of antibacterial treatment can be enhanced through joint use; 3, the exosomes can be stored at low temperature, the miRNAs can be artificially synthesized, costs are low and large-scale production can be achieved; 4, the exosomes and the multiple miRNAs have inhibitory effects on a variety of bacteria, and have wider antibacterial spectra; 5, the miRNAs act on a variety of shared signal pathways of tumor cells, can inhibit a variety of tumors, and have a wide range of antitumor application.

The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and / or who have undergone antibiotic treatment.

The present invention relates to characterizing changes in mammalian microbiota associated with antibiotic treatments and various immunological conditions and related therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, synbiotics, and antibiotics.

Use of macrolide and ketolide antibiotics for the treatment of acute exposure and diseases caused by biodefense pathogens is described.

An integrated device for diagnostic analyses used to verify the presence of bacteria in at least a biological sample mixed with a eugonic culture broth, in order to identify the type of bacteria, and to test a series of antibiotics, identifying those effective to determine the antibiotic therapy. The device comprises first examination means to verify the presence of bacteria so as to define corresponding positive biological samples and identify the type of bacteria present in the positive biological samples to define said group of antibiotics, and second examination means to verify the sensitive or resistant response of each positive biological sample to a series of antibiotics of the group of antibiotics defined by the first examination means.

The present invention relates to compositions comprising probiotic and prebiotic components, mineral salts, lactoferrin, and possibly saccharomycetes, which perform correct, effective colonisation of the probiotic components administered, with enteric consequences which involve maintaining and / or restoring intestinal health and preventing the consequences of common dysbioses of the digestive tract caused by stress, incorrect dietary habits and antibiotic treatments. Said compositions also have a concomitant anti-inflammatory and immunomodulating action.

The invention relates to a medical composition which is composed by antibiotic and pidotimod by the mass ratio of 1:0.01-15. The medical composition can be composed by the antibiotic and the pidotimod which are both compound preparation or by the antibiotic and the pidotimod which are independent medical preparation and are packaged in the same medicine box. The medical composition has the advantages that if the pidotimod or the derived salt thereof which is immunopotentiator can be supplied when the antibiotic is used for treating the bacterial infection, the treating effect of the antibiotic can be well improved, the antibiotic and the pidotimod can take effect synergistically, and the use amount of the antibiotic is reduced or the use period is shortened. The invention further discloses the preparation method and the medical application of the medical composition.

The invention provides a preparation to prevent and cure endometritis of milch cow. It comprises soluble staphylococcus enzyme, Lysozyme, bacteriostatic peptide and carrier. It has strong sterilizing effect, wide sterilizing spectrum and strong stability, easy to accept by human body. The curative effect is quick and it is convenient to use. It can be applied to prevent and cure not only endometritis of milch cow, but also bacterial infectious diseases of milch cow or other animals such as acute and chronic mastitis, colpitis, foot&mouth disease, stomatitis, etc.

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention includes a formulation comprising: (i) a therapeutically effective amount of at least one antibiotic; and (ii) a therapeutically effective amount of at least one probiotic material. The formulation is prepared in a dosage form for delivery to the gastrointestinal tract. The invention further includes a method of preventing or minimizing the proliferation of Clostridium difficile in the gastrointestinal tract of a mammal undergoing an antibiotic therapy comprising by administration of the formulation of the invention for the duration of the antibiotic therapy; methods of preventing or minimizing the occurrence of antibiotic-associated diarrhea in a mammal undergoing an antibiotic therapy that includes administering the formulation; and methods of preventing or minimizing the occurrence of antibiotic-associated colitis or pseudomembranous colitis in a patient undergoing an antibiotic therapy that includes administering the formulation.Also included are methods of reducing or preventing a failure of treatment for an antibiotic-treatable infection in a patient comprising orally administering the formulation.Described by the invention are formulations for the treatment of a C. difficile infection comprising: (i) a therapeutically effective amount of at least one antibiotic; and (ii) a therapeutically effective amount of at least one probiotic material. The antibiotic includes a non-systemic gram negative antibiotic (such as, for example, fodaximicin) and formulation is prepared in a dosage form for delivery to the gastrointestinal tract.Also included are methods of treatment of a C. difficile infection in mammal that include administering to the digestive tract of the mammal the above described formulation. Such methods provide that the likelihood that the mammal shall experience a reoccurrence of the C. difficile infection is 70% or less.

The invention relates generally to novel antibiotics and their analogs, to processes for the preparation of these novel antibiotics, to pharmaceutical compositions comprising the novel antibiotics; and to methods of using the novel antibiotics to treat or inhibit various disorders.

A method of treating respiratory disorders by delivering antibiotic to the lung alveoli using an aerosol drug delivery system.

The present invention is directed to a method of treating respiratory disorders by delivering an aerosol composition of an antibiotic drug to the lung alveoli.

This disclosure relates to methods of determining an antibiotic resistance profile of a bacterium, and methods of treating a patient with a therapeutically effective antibiotic. The methods include comparing the restriction map of the nucleic acid with a restriction map database, and determining antibiotic resistance of the bacterium by matching regions of the nucleic acid to corresponding regions in the database.